Skip to content


Akynzeo (netupitant) is a small molecule pharmaceutical. Netupitant was first approved as Akynzeo on 2014-10-10. It has been approved in Europe to treat nausea, neoplasms, and vomiting. It is known to target substance-P receptor. Akynzeo's patents are valid until 2035-09-25 (FDA).
Trade Name Akynzeo
Common Name Netupitant
Indication nausea, neoplasms, vomiting
Drug Class Tachykinin (neurokinin) receptor antagonists: NK1 receptor antagonists
Get full access now